| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| CT ORDER | CT ORDER |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 424B5 | Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3 |
Registration Statements
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| 424B5 | Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3 |
Registration Statements
|
||
| 4/A | Amendment to a previously filed 4 |
3,4,5
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
